CytoMed Therapeutics Stock Quote GDTC - Stock Price, News, Charts, Message Board, Trades

Professional-Grade Tools, for Individual Investors.

Premium

Current Price

2.90

Bid

2.70

Ask

3.50

Volume

43,736

2.685 Day's Range 3.06

1.20 52 Week Range 5.50

Market Cap

33.466M

Previous Close

2.91

Open

2.99

Last Trade

2.99

Last Trade Time

16:22:07

Financial Volume

$ 126,322

VWAP

2.8883

Average Volume (3m)

17,515

Shares Outstanding

11,540,000

Dividend Yield

PE Ratio

-8.10

Earnings Per Share (EPS)

-0.36

Revenue

518k

Net Profit

-4.13M

CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies into creating novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing C... CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies into creating novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.cytomed.sg.

Headquarters

Singapore, Sgp

Founded

CytoMed Therapeutics Ltd is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker GDTC. The last closing price for CytoMed Therapeutics was $2.91. Over the last year, CytoMed Therapeutics shares have traded in a share price range of $ 1.20 to $ 5.50.

CytoMed Therapeutics currently has 11,540,000 shares outstanding. The market capitalization of CytoMed Therapeutics is $33.58 million. CytoMed Therapeutics has a price to earnings ratio (PE ratio) of -8.10.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Update on Clinical Milestone - CytoMed Therapeutics Announces First Patient Dosed in its First-in-Human Phase I Clinical Trial of Allogeneic CAR-Gamma Delta T Cell Therapy in Patients with Advanced Solid Tumours or Haematological Malignancies

SINGAPORE, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Further to an announcement on October 7, 2024, CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based...

Form 144 - Report of proposed sale of securities

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

CytoMed Therapeutics’ first-in-human Phase I ANGELICA clinical trial using its patented donor allogeneic chimeric antigen receptor T cell (CAR-T cell) against blood and solid tumors received co-funding support from the NMRC Clinical Trial Grant

SINGAPORE, Oct. 07, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or the “Company”), a Singapore-based biopharmaceutical company focused on harnessing its...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

CytoMed Therapeutics completes cash acquisition of Cord Blood Banking Licence and Assets expanding CytoMed’s strategy to cord blood-derived biologics through subsidiary, LongevityBank

SINGAPORE, Oct. 03, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based biopharmaceutical company focused on harnessing its...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

CytoMed Therapeutics Reports Six Months Ended June 30, 2024 Financial Results and Provides Clinical and Corporate Updates

Conference call via Zoom is scheduled for October 8, 2024 at 9 a.m. ET (9 p.m. SGT) https://us06web.zoom.us/meeting/register/tZMrcOmppj0sGdA37lASywTyixRflo9w1TZT SINGAPORE, Sept. 30, 2024...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0.62	27.1929824561	2.28	3.35	2.1	56907	3.03822828	CS
4	0.37	14.6245059289	2.53	3.35	1.8302	18504	2.84219004	CS
12	1.41	94.6308724832	1.49	3.56	1.2	17515	2.53995757	CS
26	0.86	42.1568627451	2.04	3.56	1.2	41436	2.26755458	CS
52	-0.67	-18.7675070028	3.57	5.5	1.2	36091	2.89875919	CS
156	-1.1	-27.5	4	9.25	1.2	106399	4.48816879	CS
260	-1.1	-27.5	4	9.25	1.2	106399	4.48816879	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
ZEOZeo Energy Corporation	$ 2.43 (85.50%)	1.03M
MRMMEDIROM Healthcare Technologies Inc	$ 5.49 (80.00%)	1.63M
TLFTandy Leather Factory Inc	$ 5.14 (28.18%)	37.09k
WKSPWorksport Ltd	$ 0.984 (27.63%)	1.42M
FAASDigiAsia Corporation	$ 0.729 (24.32%)	165.33k
BIOABioAge Labs Inc	$ 6.6001 (-67.15%)	763.37k
LIFWMSP Recovery Inc	$ 2.73 (-15.74%)	925.81k
SMXSMX Security Matters Public Company	$ 0.42 (-14.29%)	4.05M
EEIQEpicQuest Education Group International Ltd	$ 0.8703 (-12.97%)	8.96k
ERNAEterna Therapeutics Inc	$ 0.35 (-12.48%)	227.92k
SMCISuper Micro Computer Inc	$ 47.85 (8.92%)	14.19M
RIMEAlgorhythm Holdings Inc	$ 0.0951 (3.37%)	10.52M
SVMHSRIVARU Holding Ltd	$ 0.0297 (1.37%)	7.62M
DRMADermata Therapeutics Inc	$ 1.4899 (3.47%)	6.86M
CRKNCrown Electrokinetics Corporation	$ 0.2649 (6.34%)	5.66M